Form 4: TransMedics Group Executive Tamer Khayal Executes Stock Options and Sells Shares Under 10b5-1 Plan

Tamer Khayal, Chief Commercial Officer of TransMedics Group, exercised stock options and sold shares of common stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 1, 2024, Tamer Khayal, the Chief Commercial Officer of TransMedics Group, Inc. (TMDX), executed stock options and sold shares of the company's common stock.
• The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan established on September 6, 2023.
• Khayal exercised options to acquire 1,458 shares at $38.46, 417 shares at $66.10, and 1,083 shares at $13.28.
• He then sold a total of 2,858 shares in multiple transactions at prices ranging from $146.15 to $154.86.
• Following these transactions, Khayal directly owns 20,843 shares of TransMedics Group, Inc.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions were pre-planned and do not necessarily reflect a change in the executive's view of the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's outlook or performance. It is common for executives to utilize 10b5-1 plans for scheduled stock sales.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates any significant concerns.

Key Dates